</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">DPP-4 inhibitor</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Once-weekly for adults with type 2 diabetes</td></tr><tr><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Ryzodeg<sup> </sup> (insulin degludec + insulin aspart)</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Novo Nordisk</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Soluble fixed combination of basal insulin with bolus insulin aspart </td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Once-daily for type 1 and 2 diabetes</td></tr><tr><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Semaglutide (NN9535)</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Novo Nordisk</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">GLP-1 analog</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Once-weekly for type 2 diabetes</td></tr><tr><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">SYR-472 (trelagliptin succinate)</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Takeda Pharmaceuticals and Furiex Pharmaceuticals</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">DPP-4 inhibitor</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Once-weekly oral treatment for type 2 diabetes</td></tr><tr><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Tresiba<sup> </sup> (Insulin degludec)</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Novo Nordisk</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Once-daily basal insulin</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Type 1 and 2 diabetes</td></tr><tr><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">U300</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Sanofi</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Insulin glargine</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Type 1 and 2 diabetes</td></tr></tbody></table>\n"}, "text": "Name\tSponsor/Developer\tMechanism of Action\tIndication\t \tAfrezza\tMannKind\tUltra-rapid-acting mealtime insulin therapy\tAdults with type 1 or type 2 diabetes\t \tAlbiglutide \tGlaxoSmithKline\tGlucagon-like peptide (GLP) 1 agonist\tOnce weekly for adults with type 2 diabetes\t \tAleglitazar \tRoche\tDual peroxisome proliferator-activated receptor (PPAR) alpha/gamma activation\tCardiovascular risk reduction in type 2 diabetes\t \tAlogliptin, Alogliptin and pioglitazone, Alogliptin and metformin \tTakeda Pharmaceuticals and Furiex Pharmaceuticals\tDPP-4 inhibitor\tOral treatment of type 2 diabetes, individually and in two fixed-dose combinations\t \tAtrasentan\tAbbVie\tSelective endothelin-A receptor antagonist\tOral once-daily treatment for diabetic nephropathy\t \tDulaglutide (LY2189265)\tEli Lilly\tGLP-1 analog\tOnce weekly for type 2 diabetes\t \tEmpagliflozin (BI10773)\tBoehringer Ingelheim and Eli Lilly\tSodium dependent glucose transporter 2 (SGLT2) inhibitor\tOral treatment for adults with type 2 diabetes\t \tErtugliflozin (MK-8835; PF-04971729)\tMerck & Co.